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1.1. Clinical trials
In the past 2 years, a number of landmark clinical trials have
been published which further our understanding and clinical
management of patients with atrial ﬁbrillation (AF). Two of
the major goals in the treatment of this condition include reduc-
ing progression or recurrence of the arrhythmia and decreasing
the risk of cardiovascular events, thereby improving quality of
life and decreasing morbidity. Following on from a large
body of evidence from preclinical studies, small clinical trials
and meta-analyses suggesting that blockade of the renin–
angiotensin systemhas beneﬁcial effects on the pathophysiology
26 R. Liewof AF,1 two large multicentre, placebo-controlled, randomised
trials were conducted to determine the effects of angiotensin II
receptor blockers (ARBs) on AF.
The ﬁrst of these trials, published in 2009, tested the
hypothesis that the ARB valsartan could reduce the recurrence
of AF in patients with underlying cardiovascular disease, dia-
betes or left atrial enlargement and a history of documented
AF, in addition to established treatments.2 A total of 1442 pa-
tients were enrolled into the study––722 assigned to the valsar-
tan group (target dose 320 mg) and 720 to the placebo group.
The investigators found that treatment with valsartan had no
signiﬁcant effect on AF recurrence (AF recurrence 51.4% in
the valsartan group and 52.1% in the placebo group,
p= 0.73) over a relatively short follow-up period of 1 year.
The second large ARB randomised controlled trial (RCT)
published this year evaluated whether irbesartan would reduce
the risk of cardiovascular events in patients with AF.3 Patients
with a history of risk factors for stroke and a systolic blood
pressure of at least 110 mmHg were randomly assigned to re-
ceive either irbesartan (target dose of 300 mg once daily) or
placebo. Patients for this study were already enrolled in one
of two other AF trials looking at clopidogrel plus aspirin vs
aspirin alone or vs oral anticoagulants. The investigators
found that irbesartan did not reduce cardiovascular events or
hospitalisation rates for AF (total of 9016 enrolled with a
mean follow-up of 4.1 years) and that, not surprisingly, more
patients in the irbesartan group had symptomatic hypotension
and renal dysfunction than those in the placebo group.
Although the main ﬁndings from both of these large RCTs
were negative, it should be noted that they were secondary pre-
vention studies––that is, patients already had established AF,
and also had more advanced stages of disease (over 80% of pa-
tients in both studies had a history of persistent or permanent
AF), implying that the substrate for AF was already well
established in both study groups. It might be argued that
blockade of the renin–angiotensin system may be a more effec-
tive strategy if performed earlier during the natural history of
the disease or even before AF develops (i.e., primary preven-
tion), since ACE inhibitors and ARBs may prevent, but not
necessarily reverse, the electrical and structural remodelling
that leads to the development and progression of the arrhyth-
mia. In support of this, a smaller randomised single-centre
study of 62 patients with lone AF, with no history of hyperten-
sion or heart disease, presenting to the emergency department
reported that patients given ramipril (5 mg/day) had signiﬁ-
cantly fewer AF relapses during a 3-year follow-up period than
patients given placebo.4
A signiﬁcant new addition to the pharmacological options
available for treating AF has been the emergence of droneda-
rone, a multichannel blocker with similar structural and elec-
trophysiological properties to amiodarone with the main
exception being removal of iodine and the addition of a meth-
ane-sulphonyl group.5 These structural changes result in de-
creased lipophilicity, shortened half-life (to approximately
24 h), reduced tissue accumulation and theoretically fewer side
effects than associated with amiodarone.
The ATHENA (A placebo-controlled, double-blind, paral-
lel-arm Trial to assess the efﬁcacy of dronedarone 400 mg
twice daily for the prevention of Hospitalisation or death from
any cause in patiENts with Atrial ﬁbrillation/ﬂutter) trial was
a ground-breaking study published in early 2009 evaluating the
effect of dronedarone on cardiovascular events in patients withAF.6 In this trial, 4628 patients with AF (paroxysmal or persis-
tent) or atrial ﬂutter who had an additional risk factor for
death (ageP70 years, diabetes, history of stroke/transient
ischaemic attack (TIA), systemic embolism, left atrial diame-
terP50 mm and ejection fraction 640%) were randomly
assigned to receive dronedarone (400 mg twice daily) or pla-
cebo. Over a mean follow-up of 21 ± 5 months, the investiga-
tors found that patients in the dronedarone group had a
signiﬁcantly lower primary outcome of ﬁrst hospitalisation
due to cardiovascular events or death than the placebo group
(734 (32%) vs 917 (39%), respectively, p< 0.001). Mortality
from cardiac arrhythmias was signiﬁcantly lower in the dron-
edarone group, although there was no overall difference in
all-cause mortality. Interestingly, there was also a small but
statistically signiﬁcant reduction in acute coronary syndromes
in the dronedarone group––the exact reason for this remains
unclear. Patients taking dronedarone had higher rates of bra-
dycardia, QT-prolongation, nausea, diarrhoea, rash and in-
creased serum creatinine than those receiving placebo. There
were no signiﬁcant differences in rates of thyroid- and pulmon-
ary-related adverse events between the two groups, although,
as acknowledged by the investigators in their discussion, the
follow-up period of 21 months might have been too short to
detect such adverse effects, which may take more than 2 years
to develop, as is often observed with amiodarone.
In the original ATHENA trial and also a subsequent post
hoc analysis,7 there was no evidence of harm in patients with
heart failure or those with a low ejection fraction and New
York Heart Association (NYHA) class II or III symptoms.
This contrasts with results from the earlier ANDROMEDA
(ANtiarrhythmic trial with DROnedarone in Moderate to se-
vere congestive heart failure Evaluating morbidity DecreAse)
study, which was terminated early owing to excess mortality
in the dronedarone group.8 The reason for this difference
may be attributed to the exclusion of patients with NYHA
class IV symptoms in the ATHENA study and the fact that
the ANDROMEDA study also included patients with a recent
exacerbation of heart failure. Nonetheless, in view of the re-
sults from the ANDROMEDA study, the authors warned
against use of dronedarone in patients with severe heart failure
and left ventricular dysfunction. This is reﬂected in the latest
European and American guidelines, which propose that dron-
edarone can be used as a ﬁrst-line pharmacological option in
patients with symptomatic AF, including those with structural
heart disease, coronary artery disease, hypertensive heart dis-
ease and stable heart failure with NYHA class I or II symp-
toms, but should not be used in patients with NYHA class
III or IV symptoms or recently unstable heart failure.9,10 A
number of post hoc analyses of the ATHENA trial have been
published providing further evidence for several beneﬁcial ef-
fects of dronedarone. These include a reduction in stroke risk
from 1.8% a year to 1.2% a year,11 and favourable effects on
rhythm and rate control.12
Another newly emerging drug that may have a role in the
pharmacological cardioversion of AF is the atrial-selective
antiarrhythmic drug vernakalant (RSD1235).13 Vernakalant
is one of several new agents that have been designed to target
atrial-speciﬁc ion channels and in doing so, theoretically re-
duce or limit the risk of ventricular proarrhythmia. In an
open-label trial assessing the efﬁcacy of vernakalant in the
cardioversion of AF, the intravenous agent was found to
convert 50.9% of patients with AF (out of a total of 236) to
Almanac 2011: Cardiac arrhythmias and pacing 27sinus rhythm with a median time to conversion of 14 min
among responders.14 There were no episodes of ventricular
arrhythmias and the drug was relatively well tolerated, apart
from 10 patients (4.2%) who had to discontinue treatment ow-
ing to side effects (most commonly hypotension). In a more re-
cent small randomised trial of 254 patients with recent onset
AF (3–48 h duration), vernakalant (10 min infusion of 3 mg/
kg followed by a second 10 min infusion of 2 mg/kg if patient
was still in AF after a 15 min observation period) was com-
pared with intravenous amiodarone (5 mg/kg over 60 min fol-
lowed by 50 mg maintenance infusion over 60 min).15 A
greater number of patients achieved the primary end point of
conversion to sinus rhythm within 90 min in the vernakalant
group compared with the amiodarone group (60/116 (51.7%)
compared with 6/116 (5.2%), p< 0.0001, respectively). The
median time of cardioversion in the patients receiving vernaka-
lant who responded was 11 min and this was associated with a
higher rate of symptom relief than with amiodarone. Both
drugs were well tolerated in this study and there were no cases
of ventricular arrhythmias.
A small randomised study of 61 patients with heart failure
and persistent AF contributed additional useful data towards
the continuing topic of rate vs rhythm control in patients with
heart failure and AF.16 Patients in this study were randomly as-
signed to a rhythm control strategy (oral amiodarone and elec-
trical cardioversion) or rate control with b blockers and/or
digoxin (target heart rate < 80 bpm at rest and < 110 bpm
after walking). The investigators found that restoration of sinus
rhythm in patients with AF and heart failure improved quality
of life and left ventricular function compared with a strategy of
rate control (66% in the rhythm control group were in sinus
rhythm at 1 year and 90% in the rate control group achieved
the target heart rate). For patients with AF for whom a rate
control strategy has been decided upon, the optimal target heart
rate has remained controversial. Guidelines have previously
recommended strict rate control, although this was not based
on clinical evidence. In an attempt to examine this issue, a pro-
spective, multicentre, randomised trial was conducted to test
the hypothesis that lenient rate control was not inferior to strict
rate control in preventing cardiovascular events in patients with
permanent AF.17 The investigators found that of the 614 pa-
tients recruited into the study, the frequencies of symptoms
and adverse events were similar between patients assigned to
a lenient rate control strategy (resting heart rate < 110 bpm)
and those assigned to a strict rate control strategy (resting heart
rate < 80 bpm and heart rate during moderate exercise <
110 bpm). A lenient-control strategy was easier to achieve as
more patients in this group attained their heart rate target
compared with the strict-control group (97.7% vs 67.0%,
p< 0.001).
Despite some promising results from preclinical experi-
ments and observational studies in humans,18–20 the poten-
tially beneﬁcial effects of polyunsaturated fatty acids
(PUFA) in atrial ﬁbrillation have not been conﬁrmed from
the results of several prospective randomised trials reported
recently. The largest and most comprehensive study to date de-
signed to examine this subject was a prospective, multicentre,
RCT of 663 patients with conﬁrmed paroxysmal (n= 542)
or persistent (n= 121) AF, with no substantial structural
heart disease and in sinus rhythm at baseline.21 Patients were
randomly assigned to take prescription PUFA (8 g/day) or
placebo for the ﬁrst 7 days, followed by PUFA (4 g/day) orplacebo thereafter for 24 weeks. Despite the assigned treat-
ment being relatively well tolerated in both groups and plasma
levels of eicosapentaenoic and docosahexaenoic acids being
signiﬁcantly higher in the prescription group than in the pla-
cebo group at weeks 4 and 24, the investigators found no
reduction in AF recurrence over 6 months between the two
groups. Two smaller prospective, placebo-controlled, random-
ised studies investigating the effects of PUFA in patients after
electrical cardioversion of AF22 and after cardiac surgery23
have failed to demonstrate a beneﬁcial action of PUFA in
decreasing the recurrence or incidence of AF.
2. Strategies to decrease thromboembolism
Important advances have been made in stroke prevention in
patients with AF over the past 2 years, which are likely to have
a signiﬁcant impact on future clinical management. In the RE-
LY study (Randomised Evaluation of Long-term anticoagula-
tion therapY), two ﬁxed doses (110 or 150 mg twice daily) of a
new oral direct thrombin inhibitor, dabigatran, were compared
with warfarin in over 18000 patients with AF and at least one
additional risk factor for stroke.24 The investigators found that
patients taking the 110 mg dose of dabigatran had similar rates
of stroke and systemic embolism to those receiving warfarin,
but had lower rates of major haemorrhage, while subjects tak-
ing the 150 mg dose had lower rates of stroke and systemic
embolism, with similar rates of major haemorrhage. Results
from this study were so impressive that dabigatran has since
been incorporated into the latest European and American
guidelines on AF as an alternative to warfarin for the preven-
tion of stroke and systemic embolism in patients with paroxys-
mal and permanent AF.9,25
As 80% of the active drug is excreted by the kidneys,
patients with a creatinine clearance of < 30 ml/min were ex-
cluded from the RE-LY trial; dabigatran should be used with
caution in patients with signiﬁcant renal impairment. The dose
of dabigatran approved by the US Food and Drug Adminis-
tration in October 2010 was 150 mg twice daily in patients with
non-valvular AF with a reduced dose of 75 mg twice daily for
those with mild renal impairment (creatinine clearance of 15–
30 ml/min). There are no dosing recommendations for patients
with a creatinine clearance < 15 ml/min or those undergoing
dialysis. In addition to the superiority of dabigatran (150 mg
twice daily) over warfarin for treatment of stroke and systemic
embolism, another major advantage is that there is no need for
international normalisation ratio (INR) monitoring. However,
disadvantages include the lack of a speciﬁc antidote (its half-
life is 12–17 h) and a slightly increased risk of non-haemor-
rhagic side effects, including dyspepsia. How this promising
new oral anticoagulant drug will be incorporated into current
local practices around the world will require future evaluation
and consideration. For example, there may be little to be
gained from switching patients already receiving warfarin
and with excellent INR control to dabigatran, while patients
with poor INR control or those who have newly started oral
anticoagulation may derive greater beneﬁt. Local standards
of care for anticoagulation control and follow-up may also
be an important consideration, as concluded in a subanalysis
of the RE-LY study, in which the investigators found that
sites with poor INR control and greater bleeding from
warfarin may receive greater beneﬁt from dabigatran 150 mg
twice daily.26 Other substudies following on from the original
28 R. LiewRE-LY trial have shown that the beneﬁts of dabigatran are
similar between patients who have never received a vitamin
K antagonist (VKA-naive patients) and VKA-experienced
patients,27 and that dabigatran can be used as a safe alternative
to warfarin in patients requiring cardioversion.28
In the ACTIVE A study, the ACTIVE (AF Clopidogrel
Trial with Irbesartan for prevention of Vascular Events) inves-
tigators evaluated whether the addition of clopidogrel to aspi-
rin would reduce the risk of vascular events compared with
aspirin alone in patients for whom a VKA was considered
unsuitable.29 The ACTIVE W trial had previously demon-
strated that the combination of aspirin and clopidogrel was
inferior to oral anticoagulation for the prevention of vascular
events in patients with AF at high risk of stroke.30 In the AC-
TIVE A study, involving 7554 patients and a median follow-up
of 3.6 years, the investigators found that the combination of
both antiplatelet agents reduced the risk of major vascular
events, especially stroke, compared with aspirin alone but at
the price of increased risk of major haemorrhage. The clinical
implications of the ACTIVE A and ACTIVE W trials are that
oral anticoagulation is better than the combination of aspirin
and clopidogrel in stroke prevention in patients with AF, but
for patients for whom oral anticoagulation is unsuitable, the
combination of antiplatelet agents is better than aspirin alone,
although the risk of major haemorrhage is also greater. This
reinforces the need for appropriate counselling and risk strat-
iﬁcation of patients when deciding upon the most suitable
strategy to lower the risk of vascular events in patients with
AF.
Another important randomised controlled clinical trial
including patients for whom a VKA was not suitable involved
the use of new oral direct and competitive inhibitor of factor
Xa, apixaban.31 The AVERROES (Apixaban vs acetylsalicylic
acid to prevent stroke in patients with AF who have are unsuit-
able for vitamin K antagonist treatment or for whom this treat-
ment has failed) study involved the random assignment of 5599
patients with AF (involving 522 centres in 36 countries) to apix-
aban (5 mg twice daily) or aspirin (81–324 mg/day).32 In that
study, patients with AF were agedP 50 years and had to have
at least one risk factor for stroke in addition to being unable to
take a VKA, either because it had already been shown to be
unsuitable or was deemed to be unsuitable. The investigators
found that apixaban reduced the risk of stroke or systemic
embolism without signiﬁcantly increasing the risk of bleeding
or intracranial haemorrhage and also reduced the risk of a ﬁrst
hospitalisation for a cardiovascular cause.
Recent studies in the ﬁeld of new mechanical approaches to
stroke prevention in AF include the PROTECT AF (Watch-
man Left Atrial Appendage System for Embolic Protection
in Patients with AF) study.33 In this non-inferiority study,
the efﬁcacy and safety of a new percutaneous left atrial
appendage (LAA) closure device was compared with warfarin
treatment in 707 patients with non-valvular AF. Study partic-
ipants had to have at least one risk factor for stroke (in addi-
tion to AF) and were assigned in a 2:1 ratio to receive the
LAA-closure device and subsequent discontinuation of warfa-
rin or warfarin alone (with a target INR of between 2.0 and
3.0). The LAA-closure device was successfully implanted in
88% of subjects assigned to the intervention group. After a
mean follow-up of 18 ± 10 months, the primary efﬁcacy event
rate of stroke (ischaemic or haemorrhagic) was 3.0 per 100
patient-years (95% CI 1.9–4.5) in the intervention group and4.9 per 100 patient-years (95% CI 2.8–7.1) in the control
group. Primary safety events were more common in the inter-
vention group than in the control group, and were mainly re-
lated to periprocedural complications (pericardial effusion in
4.8%, major bleeding in 3.5% and periprocedural ischaemic
stroke in 1.1%). This important study demonstrates that the
Watchman (Atritech, Plymouth, Minnesota, USA) LAA-clo-
sure device may provide an alternative strategy to oral antico-
agulation for the prevention of stroke in patients at high risk
with non-valvular AF and at high thromboembolic risk,
although the trade-off is an increased risk of periprocedural
complications related to device implantation. As with all new
interventional procedures, safety of the Watchman LAA-clo-
sure device is likely to improve with increased operator experi-
ence and familiarity with the new technology.34 Longer-term
follow-up data with an earlier percutaneous LAA-closure de-
vice, PLAATO (percutaneous left atrial appendage transcath-
eter occlusion) system,35 suggest that such devices can lower
the annualised risk of stroke/TIA compared with the expected
stroke/TIA risk assessed using the CHADS2 score (3.8% a
year and 6.6% a year, respectively), although event rates still
remain signiﬁcant.36
3. Epidemiology and genetics of AF
Epidemiological studies have shed further light on the mecha-
nisms underlying AF and identiﬁed new risk factors. Using
data from the Framingham Heart Study, investigators identi-
ﬁed a prolonged PR interval (>200 ms) as a predictor of inci-
dent AF, pacemaker implantation and all-cause mortality in
7575 individuals (mean age 47 years; 54% women).37 This
study contradicts the previously held belief that ﬁrst-degree
heart block is benign38 and raises further questions about the
mechanism by which a prolonged PR interval might increase
the risk of developing AF. In another study using 4764 partic-
ipants from the Framingham Heart Study, a new risk score
was developed aimed at predicting an individual’s absolute risk
of developing AF.39 Age, sex, body-mass index, systolic blood
pressure, treatment for hypertension, PR interval, clinically
signiﬁcant cardiac murmur and heart failure were all found
to be associated with AF (p< 0.05, except body-mass index
p= 0.08). When incorporated in a risk score, the clinical mod-
el C statistic was 0.78 (95% CI 0.76–0.80).
In a subsequent study, the same investigators looked at the
relation between a number of plasma biomarkers and incident
AF using the Framingham cohort and found that B-type natri-
uretic peptide (BNP) was a predictor of incident AF and im-
proved risk stratiﬁcation, increasing the C statistic from 0.78
(95% CI 0.75–0.81) to 0.80 (95% CI 0.78–0.83).40
In another community-based population study of older
adults (n= 5445) who participated in the Cardiovascular
Health Study, NT-proBNP was found to predict new-onset
AF, independently of any other previously described risk fac-
tor.41 Similar ﬁndings have now been reported in a Finnish co-
hort.42 The potential role of biomarkers may extend beyond
predicting incident AF––a recent study reporting that the
kinetics of plasma NT-proBNP release in patients presenting
acutely with AF provides a potential means of determining
its time of onset and the safety of cardioversion.43 There
therefore appears to be a promising role for new biomarkers
in predicting incident AF, which may help guide clinicians as
to which individuals are most at risk of developing AF and
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looking at population data in women have reported body-mass
index44 and birth weight45 to be associated with incident AF.
Furthermore, recent data from 34722 participants of the Wo-
men’s Health Study provided evidence that new-onset AF in
initially healthy women was independently associated with
all-cause and cardiovascular mortality.46
The past 2 years have seen important advances in our
understanding of the genetics and heredity of AF. Following
the landmark discovery using genome-wide association studies
on subjects from European and Chinese descent that two se-
quence variations on chromosome 4q25 are associated with
an increased risk of developing AF,47 two new AF susceptibil-
ity signals have been identiﬁed on the same chromosome.48 A
meta-analysis of four independent cohorts of European des-
cent (the Framingham Heart Study, Rotterdam Study, Van-
derbilt AF Registry and German AF Network) conﬁrmed a
signiﬁcant relationship between AF and intergenic regions on
chromosome 4.49 Interestingly, genetic variants in the chromo-
some 4q25 region also appear to modulate the risk of AF
recurrence after catheter ablation50 and are associated with
the development of AF after cardiac surgery.51,52 Whether ge-
netic sequencing of chromosome 4q25 will prove useful in risk
stratiﬁcation for the development of AF after catheter ablation
or cardiac surgery remains to be determined––at present, this
remains a distinct and promising possibility. In line with the
newly emerging genetic data on AF, studies on population-
based cohorts have also provided evidence for a heredity com-
ponent. Using data from the Framingham Heart Study, inves-
tigators found that familial AF occurred in 1185 (26.8%) and
premature familial AF occurred among 351 (7.9%) partici-
pants out of 4421 participants (11971 examinations) during
the period 1968–2007.53 The association was not attenuated
by adjustment for AF risk factors or reported AF-related ge-
netic variants. Racial factors and ancestry also appear to be re-
lated to the risk of AF. Data from white and African-
American subjects enrolled in the Cardiovascular Health
Study (CHS) and Atherosclerosis Risk in Communities
(ARIC) study suggest that European ancestry is a risk factor
for incident AF.54
4. Catheter ablation of AF
In a large prospective, multicentre trial involving 19 centres,
the use of catheter ablation was compared with antiarrhythmic
drug treatment.55 A total of 167 patients with paroxysmal AF
for whom at least one antiarrhythmic drug had failed and who
had experienced at least three AF episodes in the preceding
6 months were randomised (2:1) to undergo catheter ablation
or medical treatment. After a 9 month follow-up period, the
investigators found that catheter ablation resulted in a longer
time to treatment failure and signiﬁcantly improved quality-
of-life scores. Major 30-day treatment-related adverse events
occurred in ﬁve of 103 patients (4.9%) treated with catheter
ablation and ﬁve of 57 patients (8.8%) treated with antiar-
rhythmic drugs. An improvement in the quality of life was also
demonstrated in a prospective follow-up study of 502 symp-
tomatic subjects who underwent AF ablation.56 The improve-
ment in quality of life was sustained at 2 years in patients with
and without recurrence of AF, although the change was
greatest in patients who remained free from AF and without
antiarrhythmic drug treatment.Several well-respected, high-volume centres have recently
published their long-term outcomes following catheter ablation
for AF. The Bordeaux group reported their 5 year follow-up
data on 100 patients (86% male; age 55.7 ± 9.6 years; 63%
paroxysmal AF; 36% with structural heart disease).57 Arrhyth-
mia-free survival rates after a single catheter ablation procedure
were 40%, 37% and 29% at 1, 2 and 5 years, respectively (most
recurrences occurred over the ﬁrst 6 months). A total of 175
procedures were performed with a median of two for each pa-
tient (51 patients underwent a second procedure and 17 a third).
There were no periprocedural deaths, although major compli-
cations (cardiac tamponade requiring drainage) occurred in
three patients (3%), and minor complications (arteriovenous
(AV) ﬁstula, femoral pseudoaneurysm and asymptomatic pul-
monary vein stenosis) occurred in another three patients. The
important point to note from this study is that even in experi-
enced hands with a selected AF population (patients who are
referred for AF ablation tend to be younger and have fewer
comorbidities), there is a steady decline in arrhythmia-free sur-
vival with recurrences seen up to 5 years after ablation,
although the majority occur within the ﬁrst 6–12 months.
An experienced German centre also recently reported their
long-term follow-up data of catheter ablation in 161 patients
(75% male; age 59.8 ± 9.7 years) with symptomatic paroxys-
mal AF and normal left ventricular function.58 They found
that 75 patients (46.6%) were in sinus rhythm after the initial
procedure during a median follow-up period of 4.8 years
(0.33–5.5 years). A second procedure was performed in 66
and a third procedure in 12 patients. One patient had an aspi-
ration pneumonia that was successfully treated and two devel-
oped a sterile pericardial effusion that did not require drainage
(no other procedural complications were noted). There was a
low rate of progression to chronic AF during the follow-up
period, which was seen in only four patients (2.5%).
A group from London, UK, similarly reported their long-
term results following catheter ablation for AF in 285 patients
(75% male; mean age 57 (SD 11) years; 53% paroxysmal AF;
20% with structural heart disease) undergoing a total of 530
procedures.59 During a mean follow-up of 2.7 years (0.2–
7.4 years), freedom from AF/atrial tachyarrhythmia was 86%
for patients with paroxysmal AF and 68% for those with per-
sistent AF. Complications included three strokes/TIAs. Late
recurrence was three per 100 years of follow-up after > 3 -
years. The investigators also found that targeting complex frac-
tionated atrial electrograms (CFAEs) during the ablation
procedure improved outcome in patients with persistent AF.
However, this was not seen in a randomised study performed
by another group in which 119 patients with persistent AF were
randomised to additional CFAE ablation following pulmonary
vein isolation or no additional ablation.60
In summary, the reports on long-term success rates follow-
ing catheter ablation for AF demonstrate that the procedure
is effective in a selected group of symptomatic patients with
AF, although a signiﬁcant proportion requires more than one
ablation procedure, there are risks of periprocedural complica-
tions and AF recurrence remains a possible problem, even after
follow-up periods as long as 5 years. It should be noted that re-
ported outcomes from the different centres cannot be directly
compared, since there are differences in patient population
(e.g., percentage of patients with paroxysmal and permanent
AF, patients with structural heart disease), techniques used
(segmental pulmonary vein isolation vs wide area circumferen-
30 R. Liewtial ablation), length of follow-up and methods used to detect
AF recurrence.
A number of studies have been performed to search for new
non-invasive parameters which may help to predict AF recur-
rence following catheter ablation. These factors include renal
impairment,61 novel echo parameters such as the atrial electro-
mechanical interval,62 atrial ﬁbrosis assessed with echo63 or
MRI64 and B-type natriuretic levels.65
5. Ventricular arrhythmias and sudden cardiac death
5.1. Ventricular arrhythmias after myocardial infarction
To further understand the signiﬁcance of the occurrence and
timing of ventricular arrhythmias in the context of primary per-
cutaneous coronary intervention (PCI), a secondary analysis of
the APEX AMI (Assessment of PEXelizumab in Acute Myo-
cardial Infarction) trial was undertaken.66 Of the 5745 patients
with ST-elevation myocardial infarction presenting for primary
PCI (across 296 hospitals in 17 countries), ventricular tachycar-
dia/ventricular ﬁbrillation (VT/VF) occurred in 329 (5.7%).
Clinical outcomes and 90-day mortality were found to be worse
in those with VT/VF than in those without. Furthermore, out-
comes were worse if the VT/VF occurred late (after the end of
cardiac catheterisation) rather than early (before the end of car-
diac catheterisation). The occurrence of ventricular arrhyth-
mias remained associated with a signiﬁcantly increased
mortality after adjustment for potential confounders, although
whether they were causally related to a poorer prognosis or
simply a reﬂection of more severe heart disease is not yet clear.
In the Occluded Artery Trial-Electrophysiological Mecha-
nisms (OAT-EP) study, PCI to open a persistently occluded in-
farct-related artery after an acute myocardial infarction (AMI)
phase was compared with optimal medical treatment alone to
determine which strategy reduced markers of vulnerability to
ventricular arrhythmias.67 There were no signiﬁcant differ-
ences in heart rate variability, time-domain signal-averaged
ECG, or T-wave variability parameters (all surrogate markers
of ventricular instability) between either group at 30 days and
1 year after the AMI, which is consistent with the lack of clin-
ical beneﬁt from PCI in stable patients after AMI with persis-
tently occluded infarct-related arteries in the main OAT study.
The Cardiac Arrhythmias and Risk Stratiﬁcation After
Myocardial Infarction (CARISMA) trial was designed to inves-
tigate the incidence and prognostic signiﬁcance of arrhythmias
detected by an implantable cardiac monitor among patients
after AMI with impaired left ventricular (LV) function.68 A to-
tal of 297 patients (out of 5969 initially screened) who had had a
recent AMI and had reduced LV ejection fraction (LVEF;
640%) received an implantable loop recorder within
11 ± 5 days of the AMI and were followed-up every 3 months
for an average of 1.9 ± 0.5 years. The investigators detected a
clinically signiﬁcant number of bradyarrhythmias and tachyar-
rhythmias in these patients (28% new-onset AF, 13% non-sus-
tained VT, 10% high-degree AV block, 7% signiﬁcant sinus
bradycardia, 3% sinus arrest, 3% sustained VT and 3% VF).
In particular, intermittent high-degree AV block was associated
with a very high risk of cardiac death. The arrhythmogenic
substrate for ventricular arrhythmias following reperfusion
therapy for AMI was investigated in a study of 36 AMI survi-
vors referred for catheter ablation of VT (13 ± 9 years after
the AMI).69 Of these, 14 patients had early reperfusion duringAMI, while 22 were non-reperfused. The investigators found,
using detailed electroanatomical mapping, that scar size and
pattern were different between VT patients with and without
reperfusion during AMI, with early reperfusion and less conﬂu-
ent electroanatomical scar being associated with faster VTs.
5.2. Risk stratiﬁcation for sudden cardiac death and implantable
cardioverter deﬁbrillators
A continuing area of active research in ventricular arrhythmias
and sudden cardiac death (SCD) is in improved methods of
risk stratiﬁcation and selection of appropriate implantable car-
dioverter deﬁbrillator (ICD) recipients.70 A number of non-
invasive cardiovascular tests have recently been evaluated
among patients with an increased risk of SCD (e.g., AMI sur-
vivors and patients with coronary artery disease and cardiomy-
opathies) with promising results. These include T-wave
alternans,71,72 single-photon emission CT myocardial perfu-
sion imaging,73 sympathetic nerve imaging with 123-iodine
metaiodobenzylguanidine74 and late-gadolinium enhancement
on cardiac MRI.75 In addition, plasma biomarkers, such as
serum collagen levels, which reﬂect extracellular matrix altera-
tions that may play a part in the generation of the arrhythmo-
genic substrate,76 may have a future role in risk stratiﬁcation.
Genetic markers may also be relevant, as suggested by the
observation from a combined population of 19295 black and
white adults from the Atherosclerosis Risk In Communities
Study and the Cardiovascular Health Study that sequence
variations in the nitric oxide synthase 1 adaptor protein (NO-
S1AP) were associated with baseline QT interval and the risk
of SCD in white (but not black) US adults.77,78
Another important area requiring further clariﬁcation is the
optimal timing of ICD insertion among AMI survivors who are
deemed to be at greatest risk of SCD. The landmark DINA-
MIT study (Deﬁbrillation IN Acute Myocardial Infarction
Trial), which did not show any mortality beneﬁt from prophy-
lactic ICD insertion in patients after AMI if the device was in-
serted within 40 days of the index event,79 has been used to
guide current recommendations on ICD insertion among
AMI survivors. A recent secondary analysis of this trial con-
ﬁrmed the original ﬁndings that the reduction in sudden death
in ICD patients was offset by an increase in non-arrhythmic
deaths, which was greatest in those who received ICD shocks.80
A postmortem study looking at 105 autopsy records of pa-
tients from the VALIANT (VALsartan In Acute myocardial
infarctioN Trial) study who had died suddenly showed that
recurrent myocardial infarction or cardiac rupture accounted
for a high proportion of sudden death in the early period after
an AMI, thereby partly explaining the lack of beneﬁt of early
ICD insertion on overall mortality.81 Arrhythmic death was
more likely to occur later on (after 3 months), which is consis-
tent with the ﬁndings of improved survival among ICD recip-
ients from other major ICD trials in which the devices were
inserted at a later stage. It should be noted, however, that
20% of sudden deaths in the ﬁrst month after AMI were pre-
sumed arrhythmic as there was no speciﬁc postmortem evi-
dence of any additional abnormality that might have caused
the sudden death. A signiﬁcant proportion of patients who
have an AMI therefore appear to continue to die suddenly in
the early postinfarction period from cardiac arrhythmias.
These patients are not included in current international guide-
lines for ICD insertion and remain a group for which more
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covered by current primary prevention ICD guidelines are
those with relatively preserved LVEF after an AMI. Although
these patients are at a lower risk of SCD than those with poor
LVEF, they represent a larger proportion of AMI survivors.
Data from a multicentre Japanese study suggest that in the
era of primary PCI there is a low incidence of SCD among
AMI survivors (overall mortality was 13.1% and SCD 1.2%
over an average follow-up period of 4.2 years among 4122 pa-
tients).82 The risk was highest for those with poor LVEF
(<30%), although the absolute number at risk was greatest
in those with relatively preserved LVEF (>40%).
The Intermediate Risk Stratiﬁcation Improves Survival
(IRIS) trial published in 2009 further tested the hypothesis that
early implantation of an ICD soon after an AMI could im-
prove survival compared with optimal medical treatment.83
This was a randomised, prospective, multicentre trial which
enrolled 898 patients, 5–31 days after their AMI, who met
the following clinical criteria: LVEF 6 40% and a heart
rateP 90 bpm on the ﬁrst available ECG or non-sustained
VT (P150 bpm) during Holter monitoring. The main differ-
ence between this study and DINAMIT was a contemporary
patient population (70% had undergone PCI and the majority
were receiving optimal long-term medication) and additional
non-invasive criteria to identify a population at potentially
higher risk. However, the investigators did not ﬁnd that ICD
therapy reduced overall mortality after a mean follow-up of
37 months. Consistent with the ﬁndings from DINAMIT, the
reduced incidence of SCD among ICD recipients in the IRIS
study was offset by an increased incidence of non-SCD.
5.3. Catheter ablation of ventricular arrhythmias
The VTACH (Ventricular Tachycardia Ablation in Coronary
Heart disease) study, involving 16 centres in four European
countries, assessed the potential beneﬁt of catheter ablation
of VT before ICD implantation in patients with a history of
VT, myocardial infarction and LVEF 6 50%.84 Patients
(n= 110) were randomly allocated to receive catheter ablation
and an ICD or an ICD alone and followed-up for a mean per-
iod of 22.5 months (SD 9.0). The investigators found that pro-
phylactic VT ablation before ICD implantation prolonged the
time to VT recurrence from 5.9 months (IQR 0.8–26.7) in the
ICD-only group to 18.6 months (lower quartile 2.4 months;
upper quartile could not be determined) in the ablation and
ICD group. Complications related to the ablation procedure
occurred in two patients. This study is in accordance with an
earlier prospective randomised study of 128 patients, which
demonstrated that prophylactic catheter ablation of the ven-
tricular arrhythmogenic substrate reduced the incidence of
ICD therapy in patients with a history of myocardial infarc-
tion and previous ventricular arrhythmias.85 It should be noted
that VT ablation was performed in experienced centres in both
these trials and that there was no signiﬁcant effect of catheter
ablation on overall mortality. Whether VT ablation should
routinely be performed before ICD insertion for secondary
prevention of SCD in stable patients with previous myocardial
infarction remains to be determined.
There has been an increase in the number of publications
on epicardial ablation for VT over the past few years in view
of the realisation that not all VTs can be successfully elimi-
nated by an endocardial-only approach.86,87 In a retrospectivestudy of 156 epicardial ablations for VT (out of a total of 913
VT ablations) in three tertiary centres evaluating the safety and
mid-term complications of epicardial VT ablation, the risk of
major acute (epicardial bleeding, coronary stenosis) and de-
layed (pericardial inﬂammatory reaction, delayed tamponade,
coronary occlusion) complications related to epicardial access
was found to be 5% and 2%, respectively.88 Therefore,
although this technique can be effective in some cases, espe-
cially where endocardial ablation has failed, it is associated
with signiﬁcant morbidity and should only be performed in
centres experienced with this technique.
The prognostic signiﬁcance of frequent premature ventricu-
lar contractions (PVCs) and the effect of catheter ablation of
these ectopics has received further attention recently. In a
study of 239 asymptomatic patients with structurally normal
hearts and frequent PVCs (>1000 day1) from the right or left
ventricular outﬂow tract, a signiﬁcant negative correlation be-
tween PVC prevalence and dLVEF and positive correlation
with dLV diastolic diameter was observed over a 5.6 (SD
1.7)-year period.89 In addition to PVC burden, other factors
such as longer PVC duration, presence of non-sustained VT,
multiform PVCs and right ventricular PVCs may be associated
with a decline in LV function.90,91 Although it is well known
that catheter ablation of frequent PVCs can improve and re-
store LV function in some patients, the potential beneﬁts of
ablation in patients with normal LV function have been less
well studied. A prospective study of 49 patients with frequent
PVCs and normal baseline LVEF demonstrated that catheter
ablation can improve the subtle LV dysfunction-detected
pre-ablation using speckle tracking imaging analysis.92 How-
ever, unanswered questions remain, including beneﬁts of cath-
eter ablation on hard end points (especially mortality) and
when ablation should be performed (degree of PVC burden,
LV function, after a trial of antiarrhythmic medication?).
6. Cardiac resynchronisation therapy and pacing
Two pivotal cardiac resynchronisation therapy (CRT) clinical
trials have been published in the past 2 years that potentially
expand the indications for CRT in patients with heart failure
to those in NYHA classes I and II symptoms. MADIT-CRT
(Multicenter Automatic Deﬁbrillator Implantation Trial-
CRT) compared the use of ICD alone with CRT-D (CRT with
a deﬁbrillator component) in patients with asymptomatic or
mildly symptomatic heart failure symptoms (NYHA class I
or II), LVEF 6 30% and QRS duration ofP 130 ms.93 During
an average follow-up of 2.4 years, fewer patients in the CRT-D
group experienced the primary composite end point (all-cause
mortality and heart failure) compared with the ICD group
(17.2% compared with 25.3%, respectively, p= 0.001).
Although these results appear impressive at ﬁrst glance, closer
examination of the data reveals that the main superiority of
CRT-D was in reducing the rate of hospitalisation for heart
failure and that there was no signiﬁcant difference in mortality
between the two groups (which was 3% annually). Further-
more, the study failed to show that NYHA class I patients ful-
ﬁlling the enrolment criteria beneﬁted from CRT-D.
In RAFT (Resynchronisation-Deﬁbrillation for Ambula-
tory Heart Failure Trial), CRT-D was compared with ICD
alone in patients with NYHA class II or III heart failure,
LVEF 6 30%, intrinsic QRS durationP 120 ms or a paced
QRS duration ofP 200 ms.94 The investigators found that
32 R. Liewover a mean period of 40 months, the primary outcome (all-
cause mortality or heart failure hospitalisation) occurred in
fewer patients in the CRT-D group (33.2% compared with
40.3% in the ICD group, p< 0.001). Unlike MADIT-CRT,
RAFT demonstrated that CRT-D signiﬁcantly reduced overall
mortality and cardiovascular mortality compared with ICD
alone, although more adverse device-related events were also
seen in the CRT-D group. Possible reasons for mortality ben-
eﬁt seen in RAFT, but not MADIT-CRT, are that RAFT in-
cluded patients with more advanced disease (and a higher
proportion with ischaemic heart disease) and follow-up was
longer and more complete.
A number of subanalyses of MADIT-CRT have since been
conducted to provide further information on the ﬁndings. One
subanalysis demonstrated that women experienced signiﬁcantly
greater reductions in all-cause mortality and heart failure than
men, which was accompanied by greater echo evidence of re-
verse cardiac remodelling.95 Another subanalysis looking spe-
ciﬁcally at the echo parameters and performance between the
two groups found that CRT signiﬁcantly improved cardiac size
and performance compared with the ICD-only strategy, which
probably accounted for the outcomes beneﬁt in the CRT-D
group.96 Other studies have also provided additional echo evi-
dence that CRT in mild heart failure (NYHA class I/II) results
in major structural and functional reverse remodelling which
may prevent disease progression.97,98 The PACE (Pacing to
Avoid Cardiac Enlargement) study explored whether biventric-
ular pacing was better than right ventricular (RV) apical pacing
in preventing adverse cardiac remodelling in patients with bra-
dycardia and normal ventricular function at baseline.99 In this
small randomised study of 177 patients followed-up over a
12-month period, the investigators found that the mean LVEF
was signiﬁcantly lower in the RV-pacing group than in the
biventricular-pacing group (54.8 ± 9.1% vs 62.2 ± 7.0%,
p< 0.001), with an absolute difference of 7.4% points. How-
ever, the beneﬁcial effects of biventricular pacing on echo
parameters in this group of patients were not accompanied
by any clinical beneﬁt.
Other important and continuing areas of investigation in
the ﬁeld of CRT include how best to select candidates who
are most likely to respond to CRT and how to optimise re-
sponse. Parameters that have recently been studied to improve
patient selection include QRS morphology in MADIT-CRT
(left bundle branch block (LBBB), rather than non-LBBB, pat-
terns appear to be the predominant morphology––that is, re-
lated to response),100 baseline LV radial dyssynchrony,
discordant LV lead position, and myocardial scar in the region
of the LV pacing lead,101 and pre-pacing systolic dyssynchrony
measured by tissue Doppler imaging velocity.102 Consistent
with existing knowledge, LV lead positioning has been recon-
ﬁrmed to be important in MADIT-CRT patients103 and
patients with non-ischaemic dilated cardiomyopathy.104 The
prospective, randomised SMART-AV (SmartDelay deter-
mined AV optimisation: a comparison with other AV delay
methods used in CRT) study compared three different
methods of AV optimisation (ﬁxed empirical AV delay of
120 ms, echo-optimised AV delay, or AV optimisation with an
ECG-based algorithm) in 980 patients with a CRT device to
determine if any method was superior.105 The study found that
neither echo- or ECG-based AV optimisation was better than
a ﬁxed AV delay of 120 ms and therefore concluded that the
routine use of AV optimisation techniques was not indicated.However, the data did not exclude the possibility that AV opti-
misation might have a role in selected patients who do not re-
spond to CRT with empirical settings.
The potentially deleterious effects of chronic RV pacing on
cardiac function were re-examined in 103 patients with isolated
congenital AV block. Long-term pacing was not found to be
associated with the development of heart failure or deteriora-
tion of ventricular function in patients who were negative for
antinuclear antibody, although patients who tested positive
for the antibody were more likely to develop heart failure.106
Pacing in hypertrophic cardiomyopathy was also recently re-
examined in a single-centre study, which found some evidence
of beneﬁt from dual chamber pacing in patients with hypertro-
phic cardiomyopathy with NYHA III–IV symptoms, rest gra-
dients of > 50 mm Hg and who were refractory to other
drugs, after follow-up periods of up to 10 years.107 Another
group of patients in whom the role of pacing has remained
controversial are those with carotid sinus hypersensitivity
(CSH) with syncope. In a double-blind, placebo-controlled,
crossover study, 34 patients (aged > 55 years) with CSH and
more than three unexplained falls in the preceding 6 months
were randomised to receive a dual-chamber pacemaker with
rate-drop response programming which was switched on or
off.108 The investigators found that the pacing intervention
had no effect on the number of falls and concluded that the
role of pacing for this group of patients remains controversial.
A similar conclusion was reached in a multicentre study of 141
patients (mean age 78 years) with cardioinhibitory CSH.109
7. Inherited arrhythmogenic diseases
Major advances have been made in our understanding of the
basic mechanisms, genetics and clinical features of the inherited
arrhythmogenic diseases (IADs) over the past 2 years. Since
these cannot all be covered in this short overview, only some
of the major studies with important implications for general
cardiologists will be mentioned. The rapid expansion in our
knowledge of the genetic basis of the IADs and rise in commer-
cially available clinical genetic services has brought with it an
additional dimension to how we manage these conditions.
The reader is referred to a number of useful recently published
reviews that examine these issues in more detail.110–112
SCD without morphological evidence of heart disease ac-
counted for 23% of cases in a recent pathological study of
UK athletes.113 Potential causes of unexplained cardiac arrest
were systematically evaluated in a prospective study involving
63 patients in nine centres across Canada.114 The tests, which
included cardiac MRI, signal-averaged ECG, exercise testing,
drug challenge and selective electrophysiology (EP) testing,
resulted in a speciﬁc diagnosis (IAD, early repolarisation,
coronary spasm and myocarditis) in 35 patients (56%). The
remaining 28 patients were considered to have idiopathic
VF. Subsequent genetic testing performed in 19 patients found
evidence of causative mutations in nine (47%) of these. Family
screening of 64 family members of the nine patients with
causative mutations led to the discovery of mutations in 15
individuals (23%), who were subsequently treated. This study
provides evidence that targeted genetic testing may play a part
in helping to diagnose genetically mediated arrhythmia syn-
dromes, which may result in successful family screening.
An important study that investigated the presence of
genetic factors or modiﬁers that could partly explain the
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QT syndrome (LQTS) identiﬁed the nitric oxide synthase 1
adaptor protein (NOS1AP) as one such candidate.115 This
protein was chosen on the basis of previous studies that showed
an association between genetic variants of NOS1AP and small
quantitative increases in the QT interval and an increased risk
of death in a general population.77,116 In the study involving a
South African LQTS population (500 subjects, 205 mutation
carriers), NOS1AP variants were found to be signiﬁcantly
associated with the occurrence of symptoms, clinical severity
(including cardiac arrest and SCD) and a greater likelihood
of having a QT interval in the top 40% of values among all
mutation carriers. In another study involving 901 patients
enrolled in a prospective LQTS registry, three NOS1AP marker
single nucleotide polymorphisms (SNPs rs4657139, rs16847548
and rs10494366) were genotyped to assess the effect of variant
alleles on QTc and on the incidence of cardiac events.117 The
investigators found that variant alleles tagged by SNPs
rs4657139 and rs16847548 were associated with an average
QTc prolongation of 7 and 8 ms, respectively, whereas
rs4657139 and rs10494366 were associated with an increased
incidence of cardiac events. Furthermore, the rs10494366
minor allele was an independent prognostic marker among
patients with QTc < 500 ms, but not in the entire cohort.
These two studies demonstrate that genetic testing for variants
in the NOS1AP and tagged SNPs may be clinically useful
for risk stratiﬁcation of patients with congenital LQTS and
potentially guide the choice of therapeutic strategies.
The FINGER (France, Italy, Netherlands, GERmany) reg-
istry, one of the largest series on patients with Brugada syn-
drome (BrS) so far, involved 1029 consecutive individuals
(745 men; 72%) with BrS (with a spontaneous or drug-induced
type I ECG) who were followed-up for a median period of
31.9 months.118 The cardiac event rate per year was 7.7% in
patients with aborted SCD, 1.9% in patients with syncope
and 0.5% in asymptomatic patients. This study provides
important information that the event rate among asymptom-
atic patients with a Brugada ECG (which comprised 64% of
subjects in the registry) is low. In addition, symptoms and a
spontaneous type 1 ECG were predictors of arrhythmic events,
whereas gender, familial history of SCD, inducibility of VTs
during an EP study and the presence of an SCN5A mutation
were not predictive of arrhythmic events.
In an interesting mechanistic study of BrS, in vivo high-
density mapping using non-contact mapping array was per-
formed in the right ventricle of 18 patients with BrS and 20
controls.119 The investigators identiﬁed marked regional endo-
cardial conduction delay and heterogeneities in repolarisation
in patients with BrS and proposed that the slow-conduction
zones may have a role in the initiation and maintenance of ven-
tricular arrhythmias.
In line with these ﬁndings, an outstanding study was subse-
quently performed in which nine symptomatic patients with
BrS who had recurrent VF episodes underwent endocardial
and epicardial mapping of the right ventricle. Ablation at un-
ique abnormal low voltage sites (clustering exclusively in the
anterior aspect of the RVOT epicardium) rendered VT/VF
non-inducible in seven of the nine patients, with no recurrence
of ventricular arrhythmias in all patients over a follow-up per-
iod of 20 ± 6 months. Interestingly, normalisation of the
Brugada ECG pattern was seen in eight patients after ablation.
This important proof-of-concept study lends further supportto the notion that the underlying EP mechanism in patients
with BrS is delayed depolarisation in the RV outﬂow tract
(speciﬁcally over the anterior epicardial region) and demon-
strates for the ﬁrst time that substrate modiﬁcation may be
an effective strategy in patients with symptomatic BrS with
recurrent VF episodes.
Flecainide has recently emerged as a promising new treat-
ment for catecholaminergic polymorphic ventricular tachycar-
dia (CPVT). In a mouse model of CPVT, ﬂecainide was found
to prevent arrhythmias by inhibiting cardiac ryanodine recep-
tor-mediated calcium release.120 In the same publication, ﬂe-
cainide also completely prevented CPVT in two patients who
had remained highly symptomatic with conventional drug
treatment. In a clinical study of 33 patients who had received
ﬂecainide because of exercised-induced ventricular arrhyth-
mias despite conventional treatment, ﬂecainide was found to
either partially or completely reduce the arrhythmias in 76%
of cases.121Competing interests
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